|Bid||203.98 x 800|
|Ask||221.41 x 900|
|Day's Range||207.31 - 213.44|
|52 Week Range||181.36 - 449.34|
|Beta (5Y Monthly)||1.26|
|PE Ratio (TTM)||29.60|
|Earnings Date||Nov 01, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||317.08|
Polen Capital, an investment management company, released its “Polen U.S. SMID Company Growth” second quarter 2022 investor letter. A copy of the same can be downloaded here. In the second quarter, the fund underperformed its benchmark, the Russell 2500 Growth Index, and returned -28.35% net of fees. Poor performance of consumer discretionary and financials sectors impacted […]
Charles River Laboratories is a pharmaceutical company that specializes in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services. The cutting-edge Massachusetts-based company has been upgraded to a fundamental "buy" recommendation by a sell-side firm with a $240 price target. In the daily bar chart of CRL, below, we can see that the shares have been in a steady downtrend the past 12 months.
Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.